Table 1 Baseline characteristics of included patients
First Author Year | No. of patients Treatment/Control | Age(median) Treatment/Control | Male sex (%) | Prior systemic therapy (%) | ||
|---|---|---|---|---|---|---|
Treatment/Control | Type | Treatment | Control | |||
PD-1/L1 versus chemotherapy | ||||||
 Robert 2015 | 210/208 | 64/66 | 57.6/60.1 | Adjuvant therapy | 15.2 | 17.3 |
Neoadjuvant therapy | 0.5 | 0.5 | ||||
 Weber 2015 | 272/133 | 59/62 | 65/64 | Ipilimumab | > 99 | 100 |
Chemotherapy | 53 | 54 | ||||
Vemurafenib | 18 | 17 | ||||
Other immunotherapy | 14 | 26 | ||||
 Ribas 2015 | 180/181/179 | 62/60/63 | 58/60/64 | Ipilimumab | 100/100 | 100 |
Chemotherapy | 50/46 | 48 | ||||
Other immunotherapy | 37/34 | 31 | ||||
CTLA-4 versus chemotherapy | ||||||
 Ribas 2013 | 328/327 | 57/56 | 58/56 | Radiation therapy | 2 | 2 |
Adjuvant therapy | 2 | 3 | ||||
CTLA-4 versus placebo | ||||||
 Eggermont 2015 | 475/476 | 51/52 | 62/62 | Surgical therapy | 100 | 100 |
PD-1/L1 versus CTLA-4 | ||||||
 Schachter 2017 | 279/277/278 | 61/63//62 | 57.7/62.8/58.3 | BRAF/MET inhibitor | 18/16 | 20 |
Immunotherapy | 3/3 | 4.3 | ||||
Chemotherapy | 13/15 | 10 | ||||
CTLA-4 plus chemotherapy versus chemotherapy | ||||||
 Robert C 2011 | 250/252 | 58/56 | 60.8/59.1 | Adjuvant therapy | 26 | 27 |
CTLA-4 plus adjuvant therapy versus CTLA-4 or adjuvant therapy | ||||||
 Hodi FS 2010 | 403/137/136 | 56/57/56 | 61.3/59.1/53.7 | Adjuvant therapy | 22 | 23/24 |
Systemic therapy | 100 | 100/100 | ||||
 Hodi FS 2014 | 123/122 | 61/64 | 69.1/63.9 | Adjuvant therapy | 15 | 14 |
Systemic therapy | 31 | 30 | ||||
CTLA-4 plus PD-1/L1 versus CTLA-4 or PD-1/L1 | ||||||
 Hodi 2016 | 95/47 | 64/67 | 66/68 | Not mentioned |  |  |
 Larkin 2015 | 314/315/3161 | 59/61/59 | 65.6/64.1/63.9 | Not mentioned |  |  |
BRAF plus MEK versus BRAF | ||||||
 Larkin 2014 | 247/248 | 56/55 | 59/56 | Not mentioned |  |  |
 Long 2014 | 211/212 | 55/56.5 | 53/54 | Immunotherapy | 27 | 29 |
 Robert 2015 | 352/352 | 55/54 | 59/51 | Immunotherapy | 17 | 26 |
MEK plus chemotherapy versus chemotherapy | ||||||
 McDermott 2008 | 51/50 | 55/60 | 75/66 | Surgery | 100 | 100 |
Radation therapy | 29 | 22 | ||||
Immunotherapy | 67 | 72 | ||||
 Hauschild 2009 | 135/135 | 56/55.1 | 62/64 | Surgery | 100 | 100 |
Radation therapy | 27 | 33 | ||||
Chemotherapy | 67 | 62 | ||||
Immunotherapy | 26 | 30 | ||||
 Flaherty 2013 | 410/413 | 61/59 | 66/61 | Immunotherapy | 37 | 38 |
 Robert 2013 | 45/46 | 57/52 | 49/61 | Surgery | 89 | 83 |
Radation therapy | 18 | 26 | ||||
Chemotherapy | 7 | 2 | ||||
Immunotherapy | 42 | 48 | ||||
 Gupta 2014 | 41/42 | 62/63 | 76/64 | Not mentioned |  |  |
BRAF versus chemotherapy | ||||||
 McArthur 2014 | 187/63 | 53/50 | 60/59 | Radation therapy | 20 | 16 |
Immunotherapy | 28 | 24 | ||||
 Hauschild 2012 | 337/338 | 56/52.5 | 59/54 | Not mentioned |  |  |
MEK versus chemotherapy | ||||||
 Flaherty 2012 | 214/208 | 55/54 | 56/49 | Immunotherapy | 32 | 28 |
Chemotherapy | 67 | 65 | ||||
 Kirkwood 2012 | 104/96 | 57.1/57 | 52.9/67.7 | Not mentioned |  |  |
 Carvajal 2014 | 50/51 | 62/62 | 52/62 | Immunotherapy | 16 | 22 |